MX2013014846A - Benzoxazepinonas fusionadas como moduladoras de canales ionicos. - Google Patents

Benzoxazepinonas fusionadas como moduladoras de canales ionicos.

Info

Publication number
MX2013014846A
MX2013014846A MX2013014846A MX2013014846A MX2013014846A MX 2013014846 A MX2013014846 A MX 2013014846A MX 2013014846 A MX2013014846 A MX 2013014846A MX 2013014846 A MX2013014846 A MX 2013014846A MX 2013014846 A MX2013014846 A MX 2013014846A
Authority
MX
Mexico
Prior art keywords
ion channel
channel modulators
compounds
benzoxazepinones
fused
Prior art date
Application number
MX2013014846A
Other languages
English (en)
Other versions
MX336810B (es
Inventor
Britton Kenneth Corkey
Elfatih Elzein
Robert H Jiang
Rao V Kalla
Dmitry Koltun
Xiaofen Li
Ruben Martinez
Eric Q Parkhill
Thao Perry
Jeff Zablocki
Chandrasekar Venkataramani
Michael Graupe
Juan Guerrero
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46513866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013014846(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2013014846A publication Critical patent/MX2013014846A/es
Publication of MX336810B publication Critical patent/MX336810B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Television Systems (AREA)
  • Luminescent Compositions (AREA)

Abstract

La presente invención se relaciona con compuestos que son inhibidores de los canales de sodio y a su uso en el tratamiento de diversos estados de enfermedad, que incluyen enfermedades cardiovasculares y diabetes. En formas de realización particulares, la estructura de los compuestos es dada por la Fórmula I: (ver Fórmula) en donde Z1, Z2, Z3, Z4, X, Y, R2, R3 y R4 son como se describen en el presente documento, con métodos para la preparación y uso de los compuestos y con composiciones farmacéuticas que contienen los mismos.
MX2013014846A 2011-07-01 2012-06-29 Benzoxazepinonas fusionadas como moduladoras de canales ionicos. MX336810B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161503980P 2011-07-01 2011-07-01
US201161582160P 2011-12-30 2011-12-30
PCT/US2012/045086 WO2013006485A1 (en) 2011-07-01 2012-06-29 Fused benzoxazepinones as ion channel modulators

Publications (2)

Publication Number Publication Date
MX2013014846A true MX2013014846A (es) 2014-03-31
MX336810B MX336810B (es) 2016-02-03

Family

ID=46513866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014846A MX336810B (es) 2011-07-01 2012-06-29 Benzoxazepinonas fusionadas como moduladoras de canales ionicos.

Country Status (37)

Country Link
US (5) US8586732B2 (es)
EP (6) EP3088395B1 (es)
JP (2) JP5889407B2 (es)
KR (2) KR20160040734A (es)
CN (2) CN103857659B (es)
AP (1) AP2013007300A0 (es)
AR (1) AR086828A1 (es)
AU (1) AU2012279236B2 (es)
BR (1) BR112013032361A2 (es)
CA (1) CA2838223A1 (es)
CL (1) CL2013003598A1 (es)
CO (1) CO6821960A2 (es)
CR (1) CR20130658A (es)
CY (1) CY1117915T1 (es)
DK (1) DK2726466T3 (es)
EA (2) EA201790417A3 (es)
EC (1) ECSP13013083A (es)
ES (6) ES2792866T3 (es)
HK (6) HK1196602A1 (es)
HR (1) HRP20160952T1 (es)
HU (1) HUE029398T2 (es)
IL (2) IL230022B (es)
MD (1) MD4371C1 (es)
ME (1) ME02546B (es)
MX (1) MX336810B (es)
NZ (2) NZ716245A (es)
PE (1) PE20140690A1 (es)
PL (1) PL2726466T3 (es)
PT (1) PT2726466T (es)
RS (1) RS55024B1 (es)
SI (1) SI2726466T1 (es)
SM (1) SMT201600271B (es)
TW (4) TWI549944B (es)
UA (1) UA115529C2 (es)
UY (1) UY34171A (es)
WO (1) WO2013006485A1 (es)
ZA (1) ZA201308981B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
CN102725290B (zh) 2009-07-27 2016-03-09 吉利德科学股份有限公司 作为离子通道调节剂的稠合杂环化合物
CA2802288C (en) 2010-07-02 2018-08-21 Gilead Sciences, Inc. Triazolopyridinone compounds as ion channel modulators
EP3275870B1 (en) 2011-05-10 2020-02-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
EP3722423A1 (en) 2011-08-05 2020-10-14 Illumina, Inc. Functionalization and purification of molecules by reversible group exchange
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
JP2015504923A (ja) * 2012-01-27 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
EA034922B1 (ru) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US20140329755A1 (en) * 2013-05-01 2014-11-06 Gilead Sciences, Inc. Combination therapy for the treatment of arrhythmias or heart failure
WO2015017661A1 (en) * 2013-08-01 2015-02-05 Gilead Sciences, Inc. Compound and methods for treating long qt syndrome
SG11201600102SA (en) * 2013-08-01 2016-02-26 Gilead Sciences Inc Method of treating hypertrophic cardiomyopathy
MY181928A (en) * 2013-09-10 2021-01-14 Chromocell Corp Sodium channel modulators for the treatment of pain and diabetes
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SG11201604457XA (en) * 2013-12-19 2016-07-28 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
CN104844535A (zh) 2014-02-13 2015-08-19 吉利德科学公司 用于制备稠合杂环离子通道调节剂的方法
CA2881544A1 (en) * 2014-02-13 2015-08-13 Anna Chiu Solid forms of a late sodium current inhibitor
WO2015153153A1 (en) 2014-04-02 2015-10-08 Gilead Sciences, Inc. Methods of treating patients having implantable cardiac devices
EA201790398A1 (ru) 2014-09-24 2017-11-30 Джилид Сайэнс, Инк. Способы лечения заболевания печени
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
JP6439050B2 (ja) 2014-12-23 2018-12-19 ギリアード サイエンシーズ， インコーポレイテッド Ａｓｋ１阻害剤を調製するプロセス
WO2017007805A1 (en) 2015-07-09 2017-01-12 Gilead Sciences, Inc. Intravenous formulations of a late sodium current inhibitor
AU2017213628B2 (en) 2016-02-05 2021-07-29 Denali Therapeutics Inc. Inhibitors of receptor-interacting protein kinase 1
EP3464270B1 (en) * 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
JP2019527738A (ja) 2016-08-12 2019-10-03 ナンジン ゲイター メディテック カンパニー, リミテッドNanjing Gator Meditech Company, Ltd. プロテインキナーゼ調節剤
WO2018048977A1 (en) 2016-09-08 2018-03-15 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxazepin compounds
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
JP7208137B2 (ja) 2016-12-09 2023-01-18 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法
US20200085838A1 (en) * 2017-05-16 2020-03-19 Praxis Precision Medicines, Inc. Methods of treating epilepsy and neurodevelopmental disorders
JP7064512B2 (ja) 2017-05-17 2022-05-10 デナリ セラピューティクス インコーポレイテッド キナーゼ阻害剤およびその使用
WO2019055877A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
WO2019173761A1 (en) 2018-03-09 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services C-abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same
CA3105099A1 (en) 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)
WO2020086857A1 (en) 2018-10-24 2020-04-30 Vanderbilt University Wdr5 inhibitors and modulators
KR102172595B1 (ko) * 2018-12-19 2020-11-02 인하대학교 산학협력단 벤조옥사제핀 유도체 화합물을 포함하는 비만 예방 또는 치료용 약학 조성물
CN109879830A (zh) * 2019-03-27 2019-06-14 安徽师范大学 一种含环外双键的氧氮杂环庚烷衍生物及其制备方法
WO2020247679A1 (en) * 2019-06-04 2020-12-10 Vanderbilt University Wdr5 inhibitors and modulators
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
MX2023009682A (es) 2021-02-19 2023-10-30 Sudo Biosciences Ltd Inhibidores de tyk2 y sus usos.
TW202246232A (zh) 2021-02-19 2022-12-01 英商蘇多生物科學有限公司 Ｔｙｋ２抑制劑及其用途
WO2023137035A1 (en) 2022-01-12 2023-07-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN118556044A (zh) * 2022-01-29 2024-08-27 江苏恒瑞医药股份有限公司 稠杂环类化合物、其制备方法及其在医药上的应用
TW202409046A (zh) * 2022-04-22 2024-03-01 日商帝人製藥股份有限公司 氧雜氮雜環庚三烯衍生物

Family Cites Families (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2867618A (en) 1957-02-14 1959-01-06 Dow Chemical Co 3, 4-dihydro-2h-1, 3-benzoxazine
US2826575A (en) 1957-05-06 1958-03-11 Dow Chemical Co 3, 3'-alkylenebis
NL128591C (es) 1965-07-02
US3441649A (en) 1966-08-18 1969-04-29 Univ Minnesota Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate
US3594372A (en) 1968-08-13 1971-07-20 American Home Prod Pyrimido(4,5-e)(1,4)oxazepin-5-ones and derivatives thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4062881A (en) 1974-07-26 1977-12-13 Cincinnati Milacron Chemicals, Inc. Sulfide containing tin stabilizers
US4230705A (en) 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
US4242515A (en) 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4244953A (en) 1979-10-24 1981-01-13 American Cyanamid Company Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines
JPS5675428A (en) 1979-11-21 1981-06-22 Ayanori Takabe Hypoglycemic agent containing procainamide hydrochloride
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4812565A (en) * 1982-09-30 1989-03-14 A. H. Robins Company, Incorporated Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof
DE3382028D1 (de) * 1982-09-30 1991-01-10 Robins Co Inc A H Kondensierte aromatische oxazepinone und sulphuranaloge, ihrer herstellung und verwendung als histamin-antagonist.
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4654343A (en) 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPH061779B2 (ja) 1987-07-31 1994-01-05 田中電子工業株式会社 半導体装置の製造方法
RO96410B1 (ro) * 1987-02-16 1989-03-02 Institutul Politehnic Derivati de 1,4-benzoxazepinona si procedeu pentru prepararea lor
US4746655A (en) 1987-06-10 1988-05-24 A. H. Robins Company, Incorporated Fused aromatic-spiropiperidine oxazepinones(and thiones)
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE4010488A1 (de) 1990-03-31 1991-10-02 Hoechst Ag Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten
CA2044564A1 (en) 1990-06-28 1991-12-29 Quirico Branca Amino acid derivatives
CN1060467A (zh) 1990-09-25 1992-04-22 武田药品工业株式会社 1，3-苯并嗪衍生物、其生产方法和用途
JPH04209692A (ja) 1990-12-03 1992-07-31 Asahi Glass Co Ltd フォトクロミック材料
DE69219354T2 (de) 1991-05-10 1997-10-23 Takeda Chemical Industries Ltd Pyridinderivate, deren Herstellung und Anwendung
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5693636A (en) 1991-06-28 1997-12-02 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5674863A (en) * 1991-10-18 1997-10-07 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH061779A (ja) 1992-02-06 1994-01-11 Wakamoto Pharmaceut Co Ltd ベンズオキサジノン誘導体
JPH06107647A (ja) 1992-08-12 1994-04-19 Takeda Chem Ind Ltd １，３−ベンゾオキサジン誘導体の製造法
US5442055A (en) 1992-11-13 1995-08-15 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
US6011150A (en) 1992-11-13 2000-01-04 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
GB9225860D0 (en) 1992-12-11 1993-02-03 Smithkline Beecham Plc Novel treatment
GB9226302D0 (en) 1992-12-17 1993-02-10 Smithkline Beecham Plc Pharmaceuticals
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
DE19526173A1 (de) 1995-07-18 1997-01-30 Hoechst Ag Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung
JPH09157262A (ja) 1995-12-08 1997-06-17 Tanabe Seiyaku Co Ltd アゼチジノン誘導体及びその合成中間体の製法
US5773186A (en) 1996-02-19 1998-06-30 Fuji Photo Film Co., Ltd. Heat-sensitive recording material
GB9619492D0 (en) 1996-09-18 1996-10-30 Smithkline Beecham Plc Novel treatment
WO1998047885A1 (en) 1997-04-18 1998-10-29 Smithkline Beecham Plc A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity
US6417362B1 (en) 1997-05-30 2002-07-09 Meiji Seika Kaisha, Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
JP3964053B2 (ja) 1997-07-10 2007-08-22 三井化学株式会社 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法
AU9257998A (en) 1997-09-08 1999-03-29 Unilever N.V. Method for enhancing the activity of an enzyme
CZ290883B6 (cs) 1998-01-21 2002-11-13 Merck Sharp And Dohme Limited Triazolopyridazinové deriváty, způsob jejich výroby a farmaceutický prostředek je obsahující
EP1054877A1 (en) * 1998-02-11 2000-11-29 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
WO1999042456A2 (en) 1998-02-18 1999-08-26 Neurosearch A/S Novel compounds and their use as positive ampa receptor modulators
AU755855B2 (en) 1998-06-16 2002-12-19 Merck Sharp & Dohme Limited Triazolo-pyridine derivatives as ligands for GABA receptors
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
CA2369103A1 (en) 1999-04-09 2000-10-19 Meiji Seika Kaisha, Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
WO2000068203A1 (fr) 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Composes cycliques et leurs utilisations
US6121916A (en) 1999-07-16 2000-09-19 Eaton-Vorad Technologies, L.L.C. Method and apparatus for recognizing stationary objects with a moving side-looking radar
TR200200458T2 (tr) 1999-08-27 2002-05-21 The Procter & Gamble Company Ağartma Takviye Bileşenleri, Bileşimleri ve Çamaşır Yıkama Yöntemleri
CN1384868A (zh) 1999-08-27 2002-12-11 宝洁公司 稳定的配制组分、使用该组分的组合物和洗衣方法
AU6935700A (en) 1999-08-27 2001-03-26 Procter & Gamble Company, The Color safe laundry methods employing zwitterionic formulation components
JP2003508581A (ja) 1999-08-27 2003-03-04 ザ、プロクター、エンド、ギャンブル、カンパニー 処方成分の制御された有効化法、それを使用する組成物および洗濯方法
EP1206517A1 (en) 1999-08-27 2002-05-22 The Procter & Gamble Company Color safe laundry methods employing cationic formulation components
EP1206516A1 (en) 1999-08-27 2002-05-22 The Procter & Gamble Company Stability enhancing formulation components, compositions and laundry methods employing same
WO2001016275A1 (en) 1999-08-27 2001-03-08 The Procter & Gamble Company Fast-acting formulation components, compositions and laundry methods employing same
IL135092A0 (en) 2000-03-15 2001-05-20 Kidron Agrochem Ltd A composition for the control of pests
WO2001087883A1 (en) 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
MXPA03000952A (es) 2000-08-01 2003-09-05 Ono Pharmaceutical Co Compuestos derivados de 3,4-dihidroisoquinolina y medicamentos que los contienen, como el ingrediente activo.
WO2002018377A1 (en) 2000-08-29 2002-03-07 Pharmacia Corporation Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
DE60123665T2 (de) 2000-12-26 2007-08-16 Sankyo Co., Ltd. Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
JP4130774B2 (ja) 2001-03-09 2008-08-06 ファイザー・プロダクツ・インク 抗炎症薬としてのトリアゾロピリジン類
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP2005089298A (ja) 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
MXPA04004477A (es) 2001-11-13 2004-08-11 Schering Corp Antagonistas del neuropeptido neuroquinina-1(nk1).
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
JP2003277384A (ja) 2002-03-26 2003-10-02 Kyorin Pharmaceut Co Ltd 縮合ニ環式ピリジン誘導体
JP2003321461A (ja) 2002-04-25 2003-11-11 Kyorin Pharmaceut Co Ltd 縮合ビフェニル誘導体
US20040152696A1 (en) * 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
WO2004014880A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
WO2004014866A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
US20040242572A1 (en) 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
JPWO2004026292A1 (ja) 2002-09-20 2006-01-12 株式会社ツムラ 鎮咳薬
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
AU2003294235A1 (en) 2002-10-22 2004-05-13 The Trustees Of The University Of Pennsylvania Fragments and activity of rel protein in m. tuberculosis adn other uses thereof
CN100430386C (zh) 2002-11-07 2008-11-05 默克公司 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病
WO2004043940A1 (en) 2002-11-07 2004-05-27 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
MXPA05007389A (es) 2003-01-13 2006-02-10 Cortex Pharma Inc Metodo para el tratamiento de la deficiencia cognitiva debido a la privacion de sueno y estres.
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE10317526A1 (de) 2003-04-16 2004-11-04 Degussa Ag Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen
JP2006523704A (ja) 2003-04-17 2006-10-19 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性ヘテロサイクリックシクロペンチルテトラヒドロイソキノリンおよびテトラヒドロピリドピリジンのモジュレーター
AU2004233941A1 (en) 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
WO2004101509A2 (en) 2003-05-06 2004-11-25 Case Western Reserve University Functionalized benzoxazines, polymers and copolymers thereof
EP1646614A4 (en) 2003-07-01 2008-09-10 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
CA2533492A1 (en) 2003-07-21 2005-02-10 Solvay Pharmaceuticals Gmbh Use of 3,7-diazabicyclo[3,3,1]nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients
CN1894222A (zh) 2003-08-05 2007-01-10 沃泰克斯药物股份有限公司 作为电压门控离子通道抑制剂的稠合嘧啶化合物
US20050239767A1 (en) 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
MXPA06007023A (es) 2003-12-18 2006-08-31 Pfizer Prod Inc Metodos para tratar la inflamacion aguda en animales con inhibidores de p38 map cinasa.
AU2005219788B2 (en) 2004-03-05 2010-06-03 Nissan Chemical Corporation Isoxazoline-substituted benzamide compound and noxious organism control agent
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
WO2006002470A1 (en) 2004-06-30 2006-01-12 Monash University Chiral ligands for asymmetric catalysis
JP2006063064A (ja) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd 受容体作動剤
JP2007297283A (ja) 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
US7572783B2 (en) * 2004-08-13 2009-08-11 Amgen Inc. Substituted benzofused heterocycles
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
EP1784188B1 (en) 2004-08-23 2010-07-14 Merck Sharp & Dohme Corp. Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AU2005285083B2 (en) 2004-09-13 2011-03-10 Merck Sharp & Dohme Corp. Tricyclic anilide spirohydantoin CGRP receptor antagonists
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
WO2006048727A1 (en) 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
JP2006203875A (ja) 2004-12-24 2006-08-03 Matsushita Electric Ind Co Ltd 受信装置
WO2006091897A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
US20080176830A1 (en) * 2005-04-14 2008-07-24 Adams Nicholas D Compounds, Compositions, and Methods
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
WO2006125119A1 (en) 2005-05-17 2006-11-23 Sarcode Corporation Compositions and methods for treatment of eye disorders
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
WO2006138549A1 (en) 2005-06-17 2006-12-28 Wyeth Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists
WO2007004028A2 (en) 2005-06-30 2007-01-11 Ranbaxy Laboratories Limited Processes for the preparation of penems and its intermediate
US8932641B2 (en) 2005-08-26 2015-01-13 Amnos Co., Ltd. Dried amnion and method for drying treatment of amnion
EP1931652A2 (en) 2005-09-21 2008-06-18 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2007038209A2 (en) 2005-09-23 2007-04-05 Schering Corporation Fused tetracyclic mglur1 antagonists as therapeutic agents
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
AU2006316627A1 (en) 2005-11-18 2007-05-31 Merck Sharp & Dohme Corp. Spirolactam aryl CGRP receptor antagonists
CA2629457A1 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam bicyclic cgrp receptor antagonists
TW200734342A (en) 2005-12-15 2007-09-16 Astrazeneca Ab New compounds for the treatment of cardiac arrhythmias
ZA200804496B (en) 2005-12-16 2009-09-30 Alcon Inc Control of intraocular pressure using ALK5 modulation agents
US8013073B2 (en) 2005-12-30 2011-09-06 Chevron Oronite Company Llc Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds
EP2004643A1 (en) 2006-03-31 2008-12-24 Novartis AG Organic compounds
EP2742936A1 (en) * 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
EP2043654A2 (en) 2006-06-12 2009-04-08 Vertex Pharmaceuticals, Inc. Thienopyrimidines useful as modulators of ion channels
US20080011523A1 (en) 2006-06-29 2008-01-17 Packard Thomas G Rotor energy augmented vehicle
JP2009542673A (ja) 2006-06-29 2009-12-03 アリーナ ファーマシューティカルズ， インコーポレイテッド ヒスタミンｈ３−受容体関連障害の治療に有用なヒスタミンｈ３−受容体モジュレータ
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
WO2008007661A1 (fr) * 2006-07-11 2008-01-17 Takeda Pharmaceutical Company Limited Composé hétérocyclique tricycique et son utilisation
EP2046788A1 (en) 2006-07-12 2009-04-15 Syngeta Participations AG Triazolopyridine derivatives as herbicides
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
MX2009001963A (es) 2006-08-22 2009-03-30 Ranbaxy Lab Ltd Inhibidores de metaloproteinasa de matriz.
WO2008063287A2 (en) 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
CA2669111C (en) 2006-10-23 2016-04-12 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
US8399452B2 (en) 2006-10-28 2013-03-19 Methylgene Inc. Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors
JPWO2008053913A1 (ja) 2006-11-02 2010-02-25 塩野義製薬株式会社 Ｍｍｐ−１３を選択的に阻害するスルホニルウレア誘導体
WO2008080012A1 (en) 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
TW200836743A (en) 2007-01-29 2008-09-16 Xenon Pharmaceuticals Inc Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
AU2008219723A1 (en) 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers
JP5497429B2 (ja) 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
AU2008240202A1 (en) 2007-04-12 2008-10-23 Cv Therapeutics, Inc. Ranolazine for enhancing insulin secretion
CN101657198A (zh) * 2007-04-12 2010-02-24 Cv医药有限公司 增强胰岛素分泌的雷诺嗪
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
WO2008144483A2 (en) * 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US20110263569A1 (en) 2007-08-22 2011-10-27 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
EP2200989A1 (en) 2007-09-12 2010-06-30 Wyeth a Corporation of the State of Delaware Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
ATE513832T1 (de) 2007-12-19 2011-07-15 Genentech Inc 8-anilinoimidazopyridine und ihre verwendung als antikrebsmittel und/oder entzündungshemmende mittel
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
WO2009089027A1 (en) 2008-01-09 2009-07-16 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health Phosphodiesterase inhibitors
BRPI0908428A2 (pt) 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
US20100331310A1 (en) 2008-02-13 2010-12-30 Fumihiro Ozaki Bicycloamine derivatives
JP2009286773A (ja) 2008-03-14 2009-12-10 Bayer Cropscience Ag 殺虫性縮環式アリール類
US20110288070A1 (en) 2008-05-05 2011-11-24 ROGERS Kathryn Methods for treating cognitive disorders using inhibitors of histone deacetylase
WO2009137499A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Inhibitors of histone deacetylase
DE102008024182A1 (de) 2008-05-19 2009-11-26 Merck Patent Gmbh Verbindungen für organische elektronische Vorrichtung
MX2010013399A (es) 2008-06-06 2010-12-21 Abbott Lab Nuevos compuestos de 1,2,4-oxadiazol y sus metodos de uso.
EA020807B1 (ru) 2008-06-17 2015-01-30 Астразенека Аб Соединения пиридина
EP2307027A4 (en) 2008-07-11 2012-08-15 Neumedics TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE PROPERTIES
US8557738B2 (en) 2008-08-12 2013-10-15 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic derivative and fungicide for agricultural and horticultural use
CA2734449A1 (en) 2008-08-18 2010-02-25 Ube Industries, Ltd. Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto
JP2012502047A (ja) 2008-09-04 2012-01-26 ギリアード サイエンシーズ， インコーポレイテッド 心房細動を治療する方法
US20100113461A1 (en) 2008-10-29 2010-05-06 Gilead Palo Alto, Inc. Substituted heterocyclic compounds
WO2010074807A1 (en) * 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
WO2010056527A2 (en) * 2008-10-30 2010-05-20 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
US20100125091A1 (en) * 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Substituted heterocyclic compounds as ion channel modulators
US20100130436A1 (en) * 2008-11-25 2010-05-27 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
MX2011006108A (es) 2008-12-08 2011-11-18 Vm Pharma Llc Composiciones de inhibidores de los receptores tirosina quinasa.
SG172001A1 (en) 2008-12-08 2011-07-28 Sirtris Pharmaceuticals Inc Isoindolinone and related analogs as sirtuin modulators
JP5271069B2 (ja) 2008-12-24 2013-08-21 三和シヤッター工業株式会社 開閉装置
PE20120008A1 (es) * 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
FR2943342B1 (fr) * 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP2410843A4 (en) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc FUSIONED CORE INHIBITORS OF HEPATITIS C
US20100305093A1 (en) * 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
CN102725290B (zh) 2009-07-27 2016-03-09 吉利德科学股份有限公司 作为离子通道调节剂的稠合杂环化合物
CA2772691C (en) 2009-09-28 2017-10-03 F. Hoffmann-La Roche Ag Benzoxazepin pi3k inhibitor compounds and methods of use
WO2011042920A1 (en) 2009-10-07 2011-04-14 Decode Genetics Ehf Genetic variants indicative of vascular conditions
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
CN104341401B (zh) 2009-12-18 2017-02-15 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
CA2802288C (en) 2010-07-02 2018-08-21 Gilead Sciences, Inc. Triazolopyridinone compounds as ion channel modulators
WO2012019071A1 (en) * 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating sarcopenia
WO2012019076A1 (en) * 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury
WO2012037105A1 (en) * 2010-09-14 2012-03-22 The Trustees Of Columbia University In The City Of New York Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases
WO2012036233A1 (ja) 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
KR101630912B1 (ko) 2010-09-21 2016-06-15 퍼듀 퍼머 엘피 부프레노르핀 유사체
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
EP2643316A2 (en) * 2010-11-24 2013-10-02 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
JP5675428B2 (ja) 2011-02-25 2015-02-25 サンドビック株式会社 ベルトプレス装置
KR20140032383A (ko) 2011-03-21 2014-03-14 에프. 호프만-라 로슈 아게 Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법
EP3275870B1 (en) 2011-05-10 2020-02-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US8753674B2 (en) 2011-06-03 2014-06-17 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
NO3175985T3 (es) 2011-07-01 2018-04-28
AU2012280508A1 (en) 2011-07-01 2013-12-12 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
JP2014531454A (ja) 2011-09-21 2014-11-27 ギリアード サイエンシーズ， インコーポレイテッド グルカゴン分泌を減少させるナトリウムチャネルブロッカー
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
JP2015504923A (ja) 2012-01-27 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
US20150164871A1 (en) 2012-06-13 2015-06-18 Acesion Pharma Pharmaceutical Compositions for Combination Therapy
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
CN104844535A (zh) 2014-02-13 2015-08-19 吉利德科学公司 用于制备稠合杂环离子通道调节剂的方法
CA2881544A1 (en) 2014-02-13 2015-08-13 Anna Chiu Solid forms of a late sodium current inhibitor

Also Published As

Publication number Publication date
ES2792866T3 (es) 2020-11-12
US9598435B2 (en) 2017-03-21
MD4371C1 (ro) 2016-07-31
EP3101013B1 (en) 2020-10-21
JP2016041768A (ja) 2016-03-31
HK1225724A1 (zh) 2017-09-15
HK1225726A1 (zh) 2017-09-15
UY34171A (es) 2013-01-31
TWI549944B (zh) 2016-09-21
NZ716245A (en) 2017-07-28
HUE029398T2 (en) 2017-02-28
EP3088395A1 (en) 2016-11-02
NZ618691A (en) 2016-05-27
ES2792864T3 (es) 2020-11-12
KR101608927B1 (ko) 2016-04-04
AU2012279236B2 (en) 2015-05-14
CN103857659A (zh) 2014-06-11
HK1196602A1 (zh) 2014-12-19
EP3085694A1 (en) 2016-10-26
IL230022A0 (en) 2014-03-06
TWI478908B (zh) 2015-04-01
US8697863B2 (en) 2014-04-15
BR112013032361A2 (pt) 2016-09-06
EA027356B1 (ru) 2017-07-31
KR20160040734A (ko) 2016-04-14
US9676760B2 (en) 2017-06-13
CN106995415A (zh) 2017-08-01
KR20140033413A (ko) 2014-03-18
HK1226060A1 (zh) 2017-09-22
PL2726466T3 (pl) 2017-07-31
JP6273250B2 (ja) 2018-01-31
US20160096846A1 (en) 2016-04-07
IL256779A (en) 2018-03-29
HK1225725A1 (zh) 2017-09-15
AP2013007300A0 (en) 2013-12-31
HK1226061A1 (zh) 2017-09-22
CY1117915T1 (el) 2017-05-17
TW201531466A (zh) 2015-08-16
JP5889407B2 (ja) 2016-03-22
JP2014522847A (ja) 2014-09-08
MX336810B (es) 2016-02-03
TW201305120A (zh) 2013-02-01
ES2790633T3 (es) 2020-10-28
EP2726466A1 (en) 2014-05-07
ES2842433T3 (es) 2021-07-14
CO6821960A2 (es) 2013-12-31
WO2013006485A1 (en) 2013-01-10
US9193694B2 (en) 2015-11-24
EP3088395B1 (en) 2020-03-25
EA201790417A3 (ru) 2017-11-30
PT2726466T (pt) 2016-07-28
RS55024B1 (sr) 2016-11-30
EA201391639A1 (ru) 2014-06-30
SMT201600271B (it) 2016-08-31
EP3098218A1 (en) 2016-11-30
ME02546B (me) 2017-02-20
US20130012492A1 (en) 2013-01-10
EP2726466B1 (en) 2016-05-25
TWI622583B (zh) 2018-05-01
EP3085694B1 (en) 2020-03-25
PE20140690A1 (es) 2014-06-19
CN103857659B (zh) 2017-02-15
ZA201308981B (en) 2016-02-24
AU2012279236A1 (en) 2013-04-04
CL2013003598A1 (es) 2014-07-11
US20160347744A1 (en) 2016-12-01
ES2583415T3 (es) 2016-09-20
UA115529C2 (uk) 2017-11-27
EP3085696B1 (en) 2020-03-04
CA2838223A1 (en) 2013-01-10
TW201712000A (zh) 2017-04-01
EP3101013A1 (en) 2016-12-07
IL230022B (en) 2018-11-29
DK2726466T3 (en) 2016-09-05
EP3085696A1 (en) 2016-10-26
AR086828A1 (es) 2014-01-22
ECSP13013083A (es) 2014-01-31
ES2797128T3 (es) 2020-12-01
MD20130095A2 (en) 2014-04-30
SI2726466T1 (sl) 2016-07-29
US20130184255A1 (en) 2013-07-18
CR20130658A (es) 2014-04-15
MD4371B1 (ro) 2015-09-30
TW201837023A (zh) 2018-10-16
US20140135317A1 (en) 2014-05-15
EP3098218B1 (en) 2020-03-25
US8586732B2 (en) 2013-11-19
EA201790417A2 (ru) 2017-07-31
HRP20160952T1 (hr) 2016-10-07

Similar Documents

Publication Publication Date Title
MX336810B (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos.
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
MX2013014843A (es) Oxazepinas como moduladores del canal de iones.
MX2012015096A (es) Compuestos heterociclicos fusionados como moduladores del canal ion.
WO2011056985A3 (en) Substituted heterocyclic compounds
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
MX2016008077A (es) Compuestos heterociclicos fusionados como moduladores del canal ionico.
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
EA201301209A1 (ru) Производные пирролотриазинона в качестве ингибиторов p13k
MX2014014031A (es) Compuestos de acido carboxilico.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
EA201590562A1 (ru) Бензамиды
MX2014002112A (es) Compuestos de pirimido-piridazinona y uso de los mismos.
WO2010056527A3 (en) B-biphenyl sulfonamide compounds as ion channel modulators
EA201490573A1 (ru) Соединение бензотиазолона
EA201490231A1 (ru) Позитивные аллостерические модуляторы никотинового рецептора ацетилхолина
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
NZ720807A (en) Fused heterocyclic compounds as ion channel modulators
SA112330437B1 (ar) تركيبات دوائية محتوية على عامل منوم او مخدر وطريقة تحضيرها
EA201590452A1 (ru) СОЛИ СОЕДИНЕНИЯ БЕНЗОТИАЗОЛОНА В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРОВ

Legal Events

Date Code Title Description
FG Grant or registration